• Enables transcription of handwritten test request forms to digitized format
• Utilizes innovative AI for higher accuracy and efficiency
• Data is securely processed with ISO27001 compliant solution

Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This cutting-edge solution is now available to clinical laboratories, aiming to streamline workflows and reduce manual data entry tasks.

Revvity Transcribe AI addresses the need for laboratories to quickly and accurately process test request forms. In many laboratories, this is manual work that is time-consuming, prone to errors, and for which talent is hard to recruit. Based on initial internal data, the solution improves overall data entry workflow speed by 40 percent, including data validation.

While beneficial for a range of applications, this service is especially valuable for newborn screening (NBS) laboratories and is compatible with the EVOYA™ platform, Revvity’s NBS software solution. Public screening labs process hundreds of handwritten dried blood spot (DBS) test cards every day, and by deploying Revvity Transcribe AI, the manual data entry resource can instead be made available for other tasks within the laboratory.

“With the new Revvity Transcribe AI solution, labs can swiftly transcribe handwritten information on test request forms such as DBS filter paper cards using advanced AI-supported OCR technology,” said Norm Lord, vice president of digital products at Revvity. “This innovative service ensures that the digitized data is securely processed and seamlessly integrated into laboratory information management systems for review and verification. By automating this manually intensive process, Revvity Transcribe AI allows laboratory personnel to concentrate on other essential and time-sensitive tasks.”

Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium, October 20-24, in Omaha, Nebraska.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241022438350/en/